Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
PARP1 Inhibitors Market Assessment and Forecast – Competition Landscape, Commercial, and Pipeline Analysis, 2023-2029
PARP1 inhibitors are a class of drugs that target the enzyme poly (ADP-ribose) polymerase 1 (PARP1). PARP1 is involved in DNA repair processes, specifically base excision repair. The mechanism of action of PARP1 inhibitors involves blocking the activity of PARP1, preventing it from repairing damaged DNA. This leads to the accumulation of DNA damage and ultimately causes cell death, particularly in cancer cells that rely heavily on PARP1-mediated DNA repair pathways. PARP1 inhibitors are primarily used in the treatment of certain types of cancer, such as breast, ovarian, and prostate cancers. They have shown particular efficacy in cancers with defects in the DNA repair pathway, such as those with BRCA mutations. Additionally, PARP1 inhibitors are being investigated for their potential use in other conditions, including neurodegenerative diseases and cardiovascular disorders. According to the Centers for Diseases Control and Prevention, breast cancer is the second most common cancer among women in the USA, which accounts for 264,000 new cases and 42000 deaths every year. Companies such as AstraZeneca, Jeil, AbbVie, J&J, Merck (MSD), BeiGene, GSK, Impact Therapy, Ildong, Medison, National OncoVenture, Pfizer, Sanofi, Takeda currently cater to breast cancer, prostate cancer, peritoneal cancer segments. Lynparza (Olaparib) is one of the prominent drugs by Merck (MSD), AstraZeneca which is being used to treat sarcoma and breast carcinoma. Moreover, Zejula (niraparib) by GSK, J&J, Takeda, and Talzenna (Talazoparib) by Pfizer are other prominent drugs that are used extensively in cases of Glioblastoma and leukemia respectively, apart from getting used in before-mentioned indications. Moreover, many companies are coming up with new molecules in this space. For instance, Abbvie is one such company that is currently conducting a clinical trial of the drug ABT-888 for the treatment of endocrine gland neoplasm and breast cancer.
Key Developments
Approved PARP1 Inhibitors
Pipeline Drugs - PARP1 Inhibitor
Clinical Activity and Development of PARP1 Inhibitor
In the PARP1 inhibitor space, approximately 36 companies are focusing on 345 disease indications, and more than 600 clinical trials are being conducted in this category of drugs. For instance,
The PARP1 inhibitors are primarily used to treat breast cancer, prostate cancer, and fallopian tube cancer. PARP1 inhibitors also help to prevent ovarian epithelial cancer. For instance, Veliparib is one drug by AbbVie which is under trial for the treatment of ovarian epithelial cancer. In the treatment of fallopian tube cancer, PARP1 inhibitor Nirapirib is used widely. Through research and development, the indications in which PARP1 inhibitors can be used are getting expanded. For instance, PARP1 inhibitors are now under clinical trial for the treatment of rhabdoid tumors.
Download Free Sample Report
The approved molecules of PARP1 inhibitors are Lynparza (olaparib), Zejula (niraparib), Talzenna (talazoparib), and Rubraca (rucaparib).
The increasing prevalence of breast cancer, advanced healthcare infrastructure, and a strong emphasis on research and development are the primary drivers for market growth.
The major players in this space are AstraZeneca, AbbVie, J&J, GSK, Merck (MSD), BeiGene, Pfizer, Sanofi, and Takeda
The emergence of alternative treatment options, such as other targeted therapies or combination therapies, and stringent reimbursement policies in some regions as well as the high cost of drugs can limit their use and impact market growth.
Key Market Players